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Abstract- Acquired azole resistance in opportunistic fungi causes severe clinical problems in 
immunosuppressed individuals. This study investigated the molecular mechanisms of azole resistance in 
clinical isolates of Candida glabrata. Six unmatched strains were obtained from an epidemiological survey of 
candidiasis in immunocompromised hosts that included azole and amphotericin B susceptible and azole 
resistant clinical isolates. Candida glabrata CBS 138 was used as reference strain. Antifungal susceptibility 
testing of clinical isolates was evaluated using Clinical and Laboratory Standards Institute (CLSI) methods. 
Complementary DNA-Amplified Fragment Length Polymorphism (cDNA-AFLP) technology, semi-
quantitative RT-PCR, and sequencing were employed for identification of potential genes involved in azole 
resistance. Candida glabrata Candida drug resistance 1 (CgCDR1) and Candida glabrata Candida drug 
resistance 2 (CgCDR2) genes, which encode for multidrug transporters, were found to be upregulated in 
azole-resistant isolates (≥2-fold). Fatty acid activator 1 (FAA1) gene, belonging to Acyl-CoA synthetases, 
showed expression in resistant isolates ≥2-fold that of the susceptible isolates and the reference strain. This 
study revealed overexpression of the CgCDR1, CgCDR2, and FAA1 genes affecting biological pathways, 
small hydrophobic compounds transport, and lipid metabolism in the resistant clinical C.glabrata isolates. 
© 2016 Tehran University of Medical Sciences. All rights reserved.  
Acta Med Iran, 2016;54(7):458-464. 
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Introduction 
 
Candida glabrata, formerly rarely seen in fungal 
infections, has become an important cause of serious 
systemic infections in immunosuppressed hosts (1-3). 
Candida glabrata is an agent of bloodstream infection 
(4-6). Most clinical isolates of this organism show low 
susceptibility to azole antifungal compounds, and 
treatment of its infection is problematical. The basis of 
azole resistance in Candida species may be the 
upregulation or mutation of the ERG11 gene that 
encodes for the azole target enzyme, cytochrome p-450 
lanosterol 14-alpha demethylase (6-9). Another 
important mechanism of resistance to azole may be 
overexpression of the efflux pump genes Candida 
glabrata Candida drug resistance 1and 2 (CgCDR1 and 
CgCDR2) belonging to the ATP-binding cassette (ABC) 
transporter family (10-12). The major facilitator 
superfamily is another class of drug transporters 
involved in drug efflux pumps (12). In addition, the 
C.glabrata sensitivity to 4 Nitroquinoline N-oxide gene 
(CgSNQ2), encodes a protein belonging to the ABC 
transporter superfamily and is controlled by the 
C.glabrata pleiotropic drug response1 gene (CgPDR1). 
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The overexpression of CgPDR1could is associated 
with the development of azole resistance in C.glabrata 
(13). Several studies have demonstrated the central role 
of the CgPDR1 gene in acquired azole resistance (14-
18). CgPDR1 acquired gain-of-function (GOF) 
mutations are responsible for upregulation of many 
genes, especially ABC transporters, lipid biological 
pathway genes, and the aldo-ketoreductase gene 
(14,17,19,20). Since the molecular pathways in the 
resistant Iranian strains of C.glabrata are unclear, the 
present study investigated the transcript profile of the 
genes involved in antifungal resistance mechanisms 
using cDNA-AFLP method. This technology is a PCR-
based genome-wide expression analysis method (21). 
cDNA-AFLP has been successfully applied to assess 
expression of several genes in various organisms 
(22,23).  
 
Materials and Methods 
Yeast isolates and mycological criteria 
Six unmatched Candida glabrata isolates used in this 
study were obtained from the culture collection of an 
epidemiological survey of candidiasis in 
immunosuppressed patients at the Department of Medical 
Mycology and Parasitology in Tehran University of 
Medical Sciences (Table 1) (20). The C.glabrata strain 
CBS 138 was used as a reference. All clinical isolates 
were subcultured on CHROMagar Candida medium. The 
strains obtained were confirmed by standard biological 
criteria containing the assimilation patterns using the API 
20C AUX system (bioMérieux, France). The isolates for 
chlamydospores and pseudohyphal production were 
subcultured on cornmeal agar with 1% Tween 80. All 
isolates and the reference strain were grown on yeast 
extract, peptone, glucose (YEPD) agar plates and 
incubated for 48 h at 37°C.  
 
 
Table 1. List of clinical C.glabrata isolates used in this study with their 
fluconazole, itraconazole, and amphotericin B susceptibility 
Identification  
No.a 
Age of the 
patient (years) 
MICb(μg/ml) 
Fluconazole Itraconazole Amphotericin B 
94 62 0.25 0.5 0.25 
45 59 0.5 0.25 0.25 
51 53 64 2 0.25 
153 35 64 4 0.25 
137 35 64 2 0.25 
219 38 64 2 0.25 
a: All strains have been isolated from the oropharynx 
b: MIC, Minimum Inhibitory Concentration
 
Antifungal susceptibility assays  
The susceptibility of C.glabrata isolates to 
fluconazole, itraconazole, and amphotericin B was 
tested by the Clinical and Laboratory Standards Institute 
(CLSI), formerly the National Committee for Clinical 
Laboratory Standards, M27-A3 broth microdilution 
method (24). Briefly, final inocula of 0.5×103 to 
2.5×103 organisms per ml were distributed in wells of a 
microtiter plate in RPMI 1640 medium buffered to pH 
7.0 with 0.165M morpholinepropanesulfonic acid and 
incubated at 37°C. The MICs were determined as the 
lowest azole concentration that reduced yeast growth by 
50% compared to that of a non-treated control. 
 
RNA extraction 
Total RNA extraction was prepared from logarithmic 
growth phase cultures in YEPD broth with an RNeasy 
protect mini kit (Qiagen, Germany). For mechanical 
disruption, the yeast cell pellet was sonicated with 600 
µl volume of acid-washed glass beads (0.45-0.52 mm 
diameter). Total RNA was treated through an RNase-
free DNase treatment step (Qiagen, Germany). The 
purity of RNA template was determined with the 
NanoDrop 1000 spectrophotometer (Thermo scientific, 
USA). 
 
Complementary DNA-amplified fragment length 
polymorphism (cDNA-AFLP) 
cDNA-AFLP method was conducted as described 
previously with minor modifications (20). For 
complementary DNA (cDNA) synthesis, an equivalent 
amount (6 µg) of total RNA from each sample was 
incubated at 65°C for 10 min followed by cooling on 
ice. The master mixture included a 5x reverse 
transcriptase (RT) buffer (Fermentas, Canada), 1 µl of 
Oligo d (T) (20 pmol/µl), 2 µl of dNTPs (10 mM), 2 µl 
of Ribolock (20 U) (Fermentas, Canada), and DEPC 
treated water. Two hundred units of Moloney Murine 
Leukemia Virus (M-MuLV) RT enzyme (Fermentas, 
Germany) were added. cDNA was controlled with the 
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reference gene URA3 (orotidine-5′-phosphate 
decarboxylase). Primers were designed by using 
GenBank sequences of C.glabrata genes (as templates) 
with the Primer3 program (http://primer3.wi.mit.edu/) 
(Table 2). 
 
Table 2. Primers used for semi-quantitative RT-PCR and internal control 
Gene Primer Sequence Gene location (5 َ-3 َ) 
Product 
length 
URA3 URA3 F GGGCTCTTTAGCTCATGGTG 432-451 173bp URA3 R CAAGTGCATCGCCTTTATCA 604-585 
CgCDR1  CgCDR1 F CgCDR1R 
AAGTTGGTTTCCCCTCGTCT 
CTGCTGTAGCAATGGGTTGA 
3518-3537 
3715-3696 198bp 
CgCDR2 CgCDR2 F CgCDR2 R 
CACATCGCTAAGCAATCGAA 
AAGAACATGGCTGCACCTCT 
467-486 
705-686 239 bp 
FAA1 FAA1 F FAA1 R 
TCGTTCCTAACCACACACCA 
TCGTCATCGAAGAACACAGC 
1793-1812 
1988-1969 196bp 
 
 
The second strand was synthesized using DNA 
polymerase I (Fermentas, Germany) at 16°C for 3 h and 
precipitated with ethanol. The integrity of dscDNA was 
confirmed with the Nanodrop 1000 spectrophotometer. 
Two micrograms of dscDNA were digested with MboI 
restriction enzyme (25) (Fermentas) for 4 h at 37°C, and 
the enzyme was inactivated at 80°C for 20 min. Eight µg 
of ADMboI and 4 µg of abMboI, AFLP adaptors (Table 
3) (20), were ligated to digested dscDNA fragments by 
T4 DNA Ligase (Takara Bio Inc. Japan).The following 
protocol was used: 1 min at 65°C, decreasing to 10°C 
over 1 h. T4 DNA Ligase was added to the mixture 
incubated in advance at 16°C for 16 h. The pre-
amplification was conducted with the PreAmp adaptor 
as primer with the touchdown PCR program: 5 min at 
94°C; 20 cycles of 30 s at 94°C, 45 s initially at 65°C 
reduced 0.5°C per cycle; 20 cycles of 30 s at 94°C, 45 s 
at 55°C, and 2 min 72°C; and final extension 5 min at 
72°C. In the sensitive amplification steps, ten PCRs 
were conducted, including all sensitive adaptors 
combinations. The PCR products were visualized on 8% 
non-denaturated polyacrylamide gel electrophoresis 
(PAGE), and using silver nitrate staining. Differentiated 
transcription-derived fragments (TDFs) were generated. 
The cDNA AFLP gels were covered with a plastic seal 
and scanned. 
 
Table 3. cDNA-AFLP adaptors used in current 
study 
Adaptors Sequence (5 َ- 3 َ) 
ADMbo1 AGCACTCTCCAGCCTCTCACCGCA 
adMBO1 GATCTGCGGTGA 
Pre Amp AGCACTCTCCAGCCTCTCACCGCAGATC 
S1Mbo1 AGCACTCTCCAGCCTCTCACCGCAGATCC 
S2Mbo1 AGCACTCTCCAGCCTCTCACCGCAGATCG 
S3Mbo1 AGCACTCTCCAGCCTCTCACCGCAGATCA 
 S4Mbo1 AGCACTCTCCAGCCTCTCACCGCAGATCT 
 
 
cDNA-AFLP fragments 
The TDFs displaying differential expression were 
extracted from silver stained PAGE and re-amplified 
using the suitable sensitive adaptors (Table 3). The 
amplified fragments were cloned using a TA-cloning kit 
(Invitrogen-USA), and the recombinant plasmids were 
confirmed by using M13 universal primers with the 
following PCR conditions: 30 cycles of 94°C for 1min, 
55°C for 1 min, and 72°C for 1 min with extension of 
the final cycle at 72°C for 7 min. PCR products were 
visualized by 2% agarose gel electrophoresis. The 
recombinant plasmids including unknown DNA were 
sequenced using M13 forward (-20) and M13 reverse 
universal primers. Some TDFs were determined by 
direct sequencing (Bioneer, Korea). Sequence data were 
verified in non-redundant nucleic and protein databases 
BLAST (http://www.ncbi.nim.nih.gov/BLAST/). 
 
Semi-quantitative RT-PCR technique 
Semi-quantitative RT-PCR analysis was used to 
confirm the mRNA specific expression pattern 
visualized in the cDNA-AFLP profile (23). An 
equivalent amount (6 µg) of total RNA from clinical 
isolates and CBS standard strain was conducted for the 
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first strand cDNA synthesis as described above, and the 
evaluation pattern in cDNA-AFLP was performed using 
specific primers (Table 2) on RNA of clinical isolates 
and the reference strain. The URA3 gene was applied as 
a reference gene and internal control. The PAGE image 
was captured digitally with a Sony XC-ST50CE camera 
(Sony, Japan). The intensity of band was analyzed with 
gel analysis software UVI (Roche, Germany).  
 
Sequencing 
For reconfirming the genes which analyzed in semi-
quantitative RT-PCR technique were sequenced with the 
same primers (Bioneer, Korea). Sequence results were 
analyzed using the BLAST program. 
 
Results 
 
Standard mycological study 
     The clinical isolates and reference strain produced pink- 
purple colonies, in contrast to the white colonies exhibited 
by C.bracarensis and C.nivariensis, on CHROMagar 
Candida medium (26). The isolates could not produce 
chlamydospore and pseudohyphae on cornmeal agar with 
1% Tween 80. The isolates of Candida glabrata were able 
to assimilate glucose and trehalose and could not assimilate 
L-lysine and glycerol (27). 
 
Antifungal sensitivity 
     Susceptibility to fluconazole, itraconazole, and 
amphotericin B was examined by the CLSI method 
(document M27-A3). MICs for fluconazole, 
itraconazole, and amphotericin B are shown in Table 1. 
 
cDNA-AFLP profile 
The TDFs of cDNA-AFLP were separated on 8% non-
denaturing PAGE by silver staining (Figure 1). Several 
TDFs were visualized using ten primer combinations. 
The TDFs that showed differential expression were 
selected from the silver stained PAGE and identified 
using cloning and DNA sequencing with the sequences 
analyzed by BLAST (Table 4). Three differentially 
expressed TDFs were produced at approximately 200-
600 bp length when using S2Mbo1, S4Mbo1 and 
S1Mbo1, S3Mbo1 and S3Mbo1, and S4Mbo1 as 
sensitive primers (Figure 1). 
 
 
Figure 1. cDNA-AFLP expression profile on PAGE with silver nitrate 
staining. Sensitive amplification of cDNA-AFLP using four sensitive 
adaptor combinations, S1Mbo1, S2Mbo1, S3Mbo1, and S4Mbo1, as 
primers. The lane numbers correspond to the clinical isolates presented 
in Table 1. The arrows show differentially expressed TDFs. 
M=Marker 100 bp. 
 
 The sequencing results showed matches the TDFs with 
CgCDR1, CgCDR2, and Fatty acid activator 1 (FAA1) 
genes. An additional clone contained an unnamed 
protein sequence (Table 4). 
 
 
Table 4. Sequences of differentiated transcription-
derived fragments (TDFs) determined by cDNA-
AFLP profiles 
Accession No. Product length (bp) Explanation 
XM_ 447677.1 375 Fatty acid activator 1 
AF109723 330 
Candia glabrata 
candida drug 
resistance 1 
XM_ 446088 330 
Candia glabrata 
candida drug 
resistance 2 
XM_445802.1 300 unnamed protein product 
 
Semi-quantitative RT-PCR assay 
     In order to verify the genes found in the cDNA-
AFLP profile, a semi-quantitative RT-PCR assay was 
carried out using cDNAs from resistant and sensitive 
isolates and the CBS 138 reference strain. Figure 2 
shows the upregulation of CgCDR1, CgCDR2, and 
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FAA1 mRNA expression in resistant isolates. The semi-
quantitative RT-PCR showed CgCDR1 mRNA 
expression levels to be ≥2-fold those of the sensitive 
isolates (Figures 2,3). In addition, CgCDR2 was 
upregulated in four resistant isolates to levels 2-3-fold 
those of the susceptible isolates and the CBS 138 
reference strain (Figures 2, 3). 
 
Figure 2. Semi-quantitative RT-PCR assay. Comparison of expression 
patterns of CgCDR1, CgCDR2, and FAA1 genes in azole resistant and 
azole susceptible C.glabrata isolates. URA3 gene was used as internal 
control. The lane numbers correspond to the clinical isolates presented 
in Table 1. 
 
 
Figure 3. Expression levels of CgCDR1, CgCDR2, and FAA1 genes in 
azole resistant C.glabrata isolates compared to azole sensitive isolates. 
Expression levels are shown after normalization with the URA3 gene. 
The sample numbers correspond to the clinical isolates presented in 
Table 1. 
 
The semi-quantitative RT-PCR results of resistant 
strains showed that mRNA expression levels of the 
FAA1 gene, which encodes Faa1p, a principal long chain 
acyl-CoA synthetase (ACSL), were ≥2 fold those 
observed in the sensitive isolates and reference strain 
(Figures 2,3). The URA3 gene was used as internal 
control (Figures 2,3).  
 
Sequencing results  
     The sequencing results showed highly matched with 
CgCDR1, CgCDR2, and Fatty acid activator 1 (FAA1) 
genes of C.glabrata CBS 138 genome. 
Discussion 
 
Among non-C.albicans species, C.glabrata, has 
emerged as an important cause of mucosal and systemic 
candidiasis in immunocompromised patients. Due to the 
extensive use of antimycotic drugs in the prophylaxis of 
candidiasis, azole resistant clinical isolates of C.glabrata 
have been increasingly reported (28).  
In the present study, we used the cDNA-AFLP 
method to investigate the genes involved the resistance 
phenotypes of clinical C.glabrata isolates. The cDNA-
AFLP method is a PCR-based technique widely used to 
assess gene expression levels and the effects of agents 
controlling up- and down-regulation of genes (21,23).  
Previous studies have indicated that ABC-transporter 
genes CgCDR1, CgCDR2, and CgSNQ2 are the most 
important biological pathway in azole resistance of 
C.glabrata, eventually leading to broad cross-resistance 
to antifungal triazoles (29,30). In this study, differential 
expression of TDFs of cDNA-AFLP was determined by 
DNA sequencing. DNA sequencing showed a match 
with the CgCDR1 and CgCDR2 ABC transporter, which 
are involved in protecting organisms against cytotoxins 
and xenobiotics. Semi-quantitative analysis showed 
increased mRNA expression levels of CgCDR1 and 
CgCDR2 genes in resistant clinical C.glabrata isolates, 
whereas these genes were normally regulated in 
susceptible isolates as well as CBS reference strain.  
Upregulation and mutation of genes involved in 
sterol biosynthesis are important in azole resistance of 
Candida sp. Molecular pathways of azole resistance in 
Candida sp. are also associated with enhanced relative 
mRNA expression levels or mutation in the ERG11 
gene, which encodes cytochrome p-450 lanosterol 14-α 
demethylase, the principle step in ergosterol 
biosynthesis (31-33). The results of cDNA-AFLP profile 
and semi-quantitative RT-PCR showed FAA1 gene 
mRNA expression levels in resistant isolates ≥2-fold 
that of sensitive isolates (Figures 2,3). As expected, 
results revealed that the regulation patterns of FAA1 in 
susceptible isolates were normal. In Saccharomyces 
cerevisiae, four ACSL genes, FAA1 to FAA4, have been 
characterized (34,35). This family of enzymes plays 
important roles in lipid metabolism, fatty acid transport, 
energy production, and cell wall synthesis (36). Faa1p, 
which constitutes the major cellular activity located in 
the endoplasmic reticulum, plasma membrane and 
vesicles catalyzes acyl-CoA. A study of a fluconazole-
resistant mutant of C.glabrata reported overexpression 
of multiple genes that were found to be responsible for 
small molecules transport and cell wall function, as well 
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as lipid and fatty acid metabolism (17). In addition, 
mutation of the PDR1 gene was found to control the 
expression of many genes, such as those involved in 
sterol biological pathways (14,17). Ferrari et al., showed 
that 626 genes were regulated by at least one GOF 
mutation in CgPDR1. Analysis of the differentially 
regulated genes showed them to be involved in specific 
biological pathways. The POX1 gene CAGL0A03740g 
(fatty acyl-coenzyme A oxidase), which is involved in 
the fatty acid beta-oxidation pathway (highly similar to 
sp P13711 Saccharomyces cerevisiae), showed 
upregulation in C.glabrata. Also, the FAS1 gene 
CAGL0D00528g (Beta unit of fatty acid synthetase), 
which catalyzes the synthesis of long-chain saturated 
fatty acids, was over-expressed in resistant C.glabrata. 
The studies showed fatty acid metabolism to be essential 
for cellular life (34-36), and upregulation of genes 
belonging to this pathway in resistant C.glabrata 
provides a protective effect. The results of the present 
study underscore overexpression of the FAA1 gene as an 
important factor in lipid metabolism and suggest that 
upregulation of the ABC efflux pump genes is a 
principal mechanism of azole resistance. Many 
investigations indicate that several molecular pathways 
are involved in the development of azole resistance in 
C.glabrata. 
Candida glabrata often exhibits low susceptibility to 
fluconazole, and the incidence of all clinical forms of 
candidiasis caused by this microorganism is on the rise. 
The results of the cDNA-AFLP assay revealed that 
overexpression of the ABC efflux pump genes 
(CgCDR1, CgCDR2) and FAA1 (the principal ACSL 
gene) is associated with azole resistance in clinical 
isolates. In addition, Faa1p, which is encoded by the 
FAA1 gene, is necessary during the exponential growth-
phase for fatty acid transport, metabolism, and energy 
production. This study reports upregulation of FAA1 in 
azole resistant clinical C.glabrata isolates. Further 
studies are needed to clarify the role of FAA1 gene. 
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